Assessment of sub-maximal aerobic capacity in North African patients with chronic hepatitis B: a pilot case-control study.

Q2 Pharmacology, Toxicology and Pharmaceutics

F1000Research Pub Date : 2025-04-08 eCollection Date: 2025-01-01 DOI:10.12688/f1000research.160390.1

Jihene Bergaoui, Imed Latiri, Sawssen Mrad, Houda Chaouch, Salma Amous, Jihene Ben Abdallah, Samia Ernez Hajri, Helmi Ben Saad

{"title":"Assessment of sub-maximal aerobic capacity in North African patients with chronic hepatitis B: a pilot case-control study.","authors":"Jihene Bergaoui, Imed Latiri, Sawssen Mrad, Houda Chaouch, Salma Amous, Jihene Ben Abdallah, Samia Ernez Hajri, Helmi Ben Saad","doi":"10.12688/f1000research.160390.1","DOIUrl":null,"url":null,"abstract":"Background: Studies assessing sub-maximal aerobic capacity in non-cirrhotic chronic hepatitis B (CHB) patients are scarce. This study aimed to evaluate sub-maximal aerobic capacity in CHB patients compared to apparently healthy participants (control-group (CG)).Methods: A 6-min walk test (6MWT) was performed. The 6-min walk distance (6MWD) was recorded, along with heart-rate (HR), oxy-hemoglobin saturation (SpO 2), blood-pressure, and dyspnea ( ie ; visual analogue scale) at rest (Rest) and at the end (End) of the 6MWT. Additionally, the 6-min walk work (6MWW), and estimated cardiorespiratory and muscular chain age were calculated. Signs of physical intolerance were determined including abnormal 6MWD ( ie ; 6MWD < lower limit of normal), chronotropic insufficiency (ie ; HREnd < 60% of maximal predicted HR (MPHR)), high dyspnea ( ie ; dyspneaEnd > 5), and desaturation ( ie ; drop in SpO 2 > 5 points).Results: Compared to the CG (n=28), the CHB-group (n=26) exhibited significantly lower 6MWD by 61 meters (8%), lower 6MWW by 10%, and lower HR End by 21% (when expressed in bpm) and 17% (when expressed in %MPHR). The CHB-group, compared to the CG, included higher percentages of participants with chronotropic insufficiency and abnormal 6MWD (23.08% vs. 3.57%, and 34.61% vs. 3.57%, respectively). The CHB-group was 8.1 and 14.3 times more likely to have chronotropic insufficiency and abnormal 6MWD than the CG, respectively. CHB accelerated the aging of the cardiorespiratory and muscular chain by 11 years.Conclusion: Non-cirrhotic CHB may contribute to reduced submaximal aerobic capacity and acceleration of cardiorespiratory and muscular chain aging.","PeriodicalId":12260,"journal":{"name":"F1000Research","volume":"14 ","pages":"98"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12022957/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"F1000Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12688/f1000research.160390.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Studies assessing sub-maximal aerobic capacity in non-cirrhotic chronic hepatitis B (CHB) patients are scarce. This study aimed to evaluate sub-maximal aerobic capacity in CHB patients compared to apparently healthy participants (control-group (CG)).

Methods: A 6-min walk test (6MWT) was performed. The 6-min walk distance (6MWD) was recorded, along with heart-rate (HR), oxy-hemoglobin saturation (SpO ₂), blood-pressure, and dyspnea ( ie ; visual analogue scale) at rest (Rest) and at the end (End) of the 6MWT. Additionally, the 6-min walk work (6MWW), and estimated cardiorespiratory and muscular chain age were calculated. Signs of physical intolerance were determined including abnormal 6MWD ( ie ; 6MWD < lower limit of normal), chronotropic insufficiency (ie ; HREnd < 60% of maximal predicted HR (MPHR)), high dyspnea ( ie ; dyspneaEnd > 5), and desaturation ( ie ; drop in SpO ₂ > 5 points).

Results: Compared to the CG (n=28), the CHB-group (n=26) exhibited significantly lower 6MWD by 61 meters (8%), lower 6MWW by 10%, and lower HR _End by 21% (when expressed in bpm) and 17% (when expressed in %MPHR). The CHB-group, compared to the CG, included higher percentages of participants with chronotropic insufficiency and abnormal 6MWD (23.08% vs. 3.57%, and 34.61% vs. 3.57%, respectively). The CHB-group was 8.1 and 14.3 times more likely to have chronotropic insufficiency and abnormal 6MWD than the CG, respectively. CHB accelerated the aging of the cardiorespiratory and muscular chain by 11 years.

Conclusion: Non-cirrhotic CHB may contribute to reduced submaximal aerobic capacity and acceleration of cardiorespiratory and muscular chain aging.

查看原文本刊更多论文

评估北非慢性乙型肝炎患者的亚最大有氧能力：一项试点病例对照研究。

背景：评估非肝硬化慢性乙型肝炎（CHB）患者亚最大有氧能力的研究很少。本研究旨在评估慢性乙型肝炎患者与表面健康参与者（对照组）的亚最大有氧能力。方法：进行6分钟步行试验（6MWT）。记录6分钟步行距离（6MWD），同时记录心率（HR）、氧血红蛋白饱和度（spo2）、血压和呼吸困难(即；视觉模拟比例尺)在休息（rest）和结束（end）的6MWT。此外，还计算了6分钟步行工作（6mw），以及估计的心肺和肌肉链年龄。身体不耐受的迹象包括6MWD异常(即；6MWD <正常下限值)，变时功能不全(即；HREnd <最大预测HR （MPHR）的60%)，高度呼吸困难(即；呼吸困难结束> 5)，去饱和(即；SpO指数下跌0.5个点)。结果：与CG （n=28）相比，chb组（n=26） 6MWD显著降低61米（8%），6MWW显著降低10%，HR End显著降低21%（以bpm表示）和17%（以%MPHR表示）。与CG组相比，chb组出现变时功能不全和6MWD异常的比例更高（分别为23.08%对3.57%，34.61%对3.57%）。chb组发生变时功能不全和6MWD异常的可能性分别是CG组的8.1倍和14.3倍。慢性乙型肝炎使心肺和肌肉链的衰老加快了11年。结论：非肝硬化慢性乙型肝炎可能导致亚最大有氧能力降低，心肺和肌肉链老化加速。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

F1000Research Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)

CiteScore

5.00

自引率

0.00%

发文量

1646

审稿时长

1 weeks

期刊介绍： F1000Research publishes articles and other research outputs reporting basic scientific, scholarly, translational and clinical research across the physical and life sciences, engineering, medicine, social sciences and humanities. F1000Research is a scholarly publication platform set up for the scientific, scholarly and medical research community; each article has at least one author who is a qualified researcher, scholar or clinician actively working in their speciality and who has made a key contribution to the article. Articles must be original (not duplications). All research is suitable irrespective of the perceived level of interest or novelty; we welcome confirmatory and negative results, as well as null studies. F1000Research publishes different type of research, including clinical trials, systematic reviews, software tools, method articles, and many others. Reviews and Opinion articles providing a balanced and comprehensive overview of the latest discoveries in a particular field, or presenting a personal perspective on recent developments, are also welcome. See the full list of article types we accept for more information.